Anika Therapeutics, Inc. — Q3 2015 Form 10-Q Summary
Business context and reporting period
Anika develops, manufactures, and commercializes hyaluronic-acid-based products for tissue protection, healing, and repair. Its principal franchises include orthobiologics, dermal, surgical, ophthalmic, and veterinary products. The filing covers the unaudited three and nine months ended September 30, 2015, compared with the corresponding 2014 periods.
Financial performance and liquidity
| Metric | Q3 2015 | Q3 2014 | 9M 2015 | 9M 2014 |
|---|---|---|---|---|
| Total revenue | $23.7 million | $22.1 million | $62.1 million | $82.3 million |
| Product revenue | $23.7 million | $22.0 million | $62.1 million | $57.6 million |
| Operating income | $13.1 million | $10.3 million | $31.1 million | $49.4 million |
| Net income | $8.4 million | $6.2 million | $19.7 million | $30.5 million |
| Diluted EPS | $0.55 | $0.40 | $1.29 | $1.97 |
| Operating cash flow | Not separately provided | Not separately provided | $23.8 million | $25.2 million |
- Q3 product revenue increased 8%; nine-month product revenue also increased 8%. Total nine-month revenue declined 25% because 2014 included approximately $24.7 million of MONOVISC licensing and milestone revenue.
- Product gross profit was $18.5 million in Q3 and $47.3 million for nine months. Product gross margin improved to 78% and 76%, respectively, from 74% and 73% in the comparable periods.
- Approximate operating margins were 55.5% in Q3 2015 versus 46.6% in Q3 2014, and 50.0% for the first nine months versus 60.0% in the prior-year period. The nine-month comparison was affected by the 2014 milestone revenue.
- Q3 net income increased 36%, while nine-month net income decreased 35%. The effective tax rates were 36% for Q3 and 37% for nine months, versus 40% and 38% in 2014.
- Cash and cash equivalents were $108.5 million at September 30, 2015, compared with $100.2 million at December 31, 2014. Cash, cash equivalents, and investments totaled approximately $130.5 million, and working capital was approximately $155.0 million.
- The balance sheet reports no borrowings or debt balance. Total liabilities were $23.1 million and stockholders’ equity was $199.8 million at September 30, 2015.
- Cash flow from operations was $23.8 million. Investing activities used $17.3 million, including $2.0 million of property and equipment purchases; financing activities provided $2.0 million.
Material changes versus the prior comparable period
- Orthobiologics revenue increased 8% in Q3 and 6% for nine months, driven by MONOVISC and ORTHOVISC demand, including international growth. Mitek completed its planned MONOVISC inventory reduction during Q3.
- Veterinary revenue increased 22% in Q3 and 48% for nine months, while nine-month dermal and ophthalmic revenue increased 21% and 35%, respectively. Surgical revenue declined 3% in both periods, primarily due to foreign currency effects.
- Approximately $0.5 million of Q3 product revenue related to a non-recurring MONOVISC pricing arrangement; management stated that no additional revenue from this arrangement is expected.
- Licensing, milestone, and contract revenue was only $5,561 in Q3 and $16,732 for nine months, compared with $24.7 million for the first nine months of 2014, when MONOVISC approval and commercialization milestones were recognized.
- Research and development expense declined 3% for nine months, primarily because 2014 included higher CINGAL pivotal-trial activity. SG&A expense declined 10% for nine months, partly due to the full amortization of certain intangible assets and lower 2014 termination-related costs.
- Accounts receivable increased to $23.4 million from $17.2 million at year-end 2014, while inventories declined modestly to $12.1 million.
Outlook, risks, contingencies, and unusual items
- Management expects continued 2015 growth in orthobiologics, dermal, and veterinary revenue, but expects surgical revenue to be slightly lower because of foreign currency effects and ophthalmic revenue to decline following expiration of the AMVISC supply agreement.
- Research and development spending is expected to increase as the company advances HYALOFAST and other clinical programs. The FDA approved the HYALOFAST IDE in July 2015, with phase III enrollment expected by year-end.
- CINGAL regulatory activities continued, including a September 2015 FDA Office of Combination Products meeting and a subsequent formal request for designation. Health Canada approval was received in early November 2015.
- The company expects approximately $25 million of spending over the next 18 to 24 months to establish additional Bedford manufacturing capacity for HYAFF-based products.
- On October 9, 2015, Anika S.r.l. entered a 15-year build-to-suit lease for a 25,000-square-foot facility in Padova, Italy. Initial annual rent is €360,000, with commencement expected in the fourth quarter of 2016 and renewal options.
- Management believes existing cash and investments are sufficient for at least the next twelve months. Future funding could be required if operating cash and capital resources are insufficient; available financing may not be obtainable on acceptable terms.
- Key risks include regulatory approvals, clinical and product development, competition, supply interruptions, product quality, intellectual-property protection, pricing pressure, healthcare policy, foreign currency exposure, international operations, and dependence on key personnel.
- The company reported routine legal proceedings but does not expect them to have a material adverse effect. No material changes were reported to prior-year risk factors, market risks, or internal controls.
Important facts for investors to verify
- Whether MONOVISC U.S. demand and Mitek inventory normalization support continued orthobiologics growth after the non-recurring pricing benefit ends.
- The timing, cost, and expected returns of the approximately $25 million Bedford manufacturing expansion and the Padova lease commitment.
- Regulatory progress and commercialization prospects for CINGAL, HYALOFAST, and HYALOSPINE.
- The sustainability of the improved product gross margin and the effect of future product mix and foreign exchange movements.
- Accounts-receivable collection trends and working-capital requirements as revenue grows.
- The effect of lower milestone revenue, higher planned R&D spending, and potential future financing needs on cash generation.